Education ▼

Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

SPECIALTY TOPICS

CURRENTLY VIEWING
Chronic Lymphocytic Leukemia

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Chronic Lymphocytic Leukemia

BTK and BCL-2 Inhibitors Reach New Milestones in CLL

Michael Choi, MD, sheds light on the data with BTK and BCL-2 inhibitors in CLL and shares ongoing research being done with PI3K inhibitors and CAR T-cell therapy in the relapsed/refractory setting.
Read More >>

Expert Highlights Evolution of BTK Inhibitors in CLL

CD19-Directed CAR-NK Cell Therapy Elicits Responses in Non-Hodgkin Lymphoma and CLL

Novel Agents, Approaches Advancing CLL Paradigm

EU Panel Recommends Frontline Venetoclax/Obinutuzumab in CLL

Advances Continue at Rapid Pace in CLL Paradigm

View More Stories >>

View Conference Coverage

2020 Transplantation & Cellular Therapy Meetings

2020 Winter Lung Cancer Conference

2020 Genitourinary Cancers Symposium

2020 SGO Winter Meeting

2020 Gastrointestinal Cancers Symposium

Dr. Danilov on ELEVATE-TN Trial Results in CLL

Dr. Woyach on Ibrutinib Regimens in Frontline CLL

Dr. Fakhri on Ongoing Clinical Trials in CLL

Dr. Furman on Acalabrutinib Monotherapy in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Combining Targeted Therapies in CLL

Ibrutinib + Venetoclax for CLL

Venetoclax in R/R CLL

Progression on Frontline Ibrutinib in CLL

Treatment for Younger Fit Patients With CLL

The Role of Venetoclax + Rituximab in CLL

Resistance Mechanisms Associated With BTK Inhibitors

OncLive houses thousands of videos that provide updates and information.
See more Videos

BTK Inhibitors in Chronic Lymphocytic Leukemia

Genomic Profiling in Chronic Lymphocytic Leukemia

Venetoclax-Based Regimens as First-Line Therapy in CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

$Novel Approaches to Treating Relapsed/Refractory CLL$

$Continuing Therapy in Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Other Promising Strategies in CLL

This expert panel discussion led by William Wierda, MD, focuses on promising strategies available for the treatment of chronic lymphocytic leukemia. Dr. Wierda is joined in this discussion by Steven Coutre, MD; Matthew S. Davids, MD, MMSc; Nicole Lamanna, MD; and Shuo Ma, MD, PhD.

View Now

The Use of Novel PI3K Inhibitors in CLL

In this segment William Wierda, MD, PhD, leads a panel discussion regarding the use of novel PI3K inhibitors in chronic lymphocytic leukemia.

View Now

Featured Video

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

Christina Tan, MD, MPH, state epidemiologist, assistant commissioner, New Jersey Department of Health, discusses the potential impact of the novel coronavirus on patients with cancer. View now

OncLive News Network On Location: 2020 Transplantation & Cellular Therapy Meetings